What is ADTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ADTX?

P/E (TTM) is n/a and 52-week range is $0.00 to $18232.56 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ADTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ADTX?

The company profile lists revenue (TTM) near $710M, net income (TTM) near $-257.06T, EPS (TTM) near $-205055.95 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Aditxt Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Richmond, Virginia, US, 998M shares outstanding, ISIN US0070258779 when available from company profile and filing metadata.

Aditxt Inc

$ADTX

Health Care · Biotechnology

IR Run Scenarios

$0.01

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The firm operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. The company is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.

Employees

Website

aditxt.com/

IPO

2020-06-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)